Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9738285 | 0.83 | F2 (0.53) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL135563 | 0.83 | F2 (0.53) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL18025296 | 0.81 | ALDH1A1 (0.50) | HTTLMNACA12CA1CA2 | |
| SCHEMBL20187458 | 0.80 | ALDH1A1 (0.53) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL127246 | 0.78 | F2 (0.57) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL17493464 | 0.76 | GAA (0.53) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL12377380 | 0.75 | GAA (0.52) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL5138891 | 0.75 | F2 (0.59) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL17137206 | 0.75 | KMT2A (0.51) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL23066856 | 0.74 | ALDH1A1 (0.45) | F2PRSS1PRSS2PRSS3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| EP-3585774-B1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11168078-B2 | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20210070742-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | FOCHON BIOSCIENCES, LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-10927086-B2 | Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3746075-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-20160016923-A1 | S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970264-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105246890-A | Pyrrolo[2, 3-b]pyridine cdk9 kinase inhibitors | ABBVIE INC | 2016-01-13 | — | — | CN | disclosed |
| US-9156848-B2 | Treating diabetes with dipeptidyl peptidase-IV inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150175609-A1 | TREATING DIABETES WITH DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2014151444-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927086-B2 | Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | F2 3129/4885PRSS1 509/4885PRSS2 915/4885 |
| US-20160016923-A1 | S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | F2 2232/4885PRSS1 286/4885PRSS2 852/4885 |
| US-20210070742-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TST | F2 2672/4885PRSS1 104/4885PRSS2 91/4885 |
| US-20150175609-A1 | TREATING DIABETES WITH DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | F2 2030/4885PRSS1 54/4885PRSS2 51/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | F2 1338/4885PRSS1 1118/4885PRSS2 1044/4885 |
| US-11168078-B2 | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, TST | F2 2672/4885PRSS1 104/4885PRSS2 91/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | F2 4861/4885PRSS1 1537/4885PRSS2 444/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | F2 4844/4885PRSS1 2691/4885PRSS2 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.